Natera, Personalis team up on personalized oncology

By staff writers

February 17, 2021 -- Cell-free DNA testing company Natera and advanced genomics firm Personalis have partnered on a personalized oncology project targeted at the assessment of molecular residual disease (MRD).

Personalis' NeXT tumor profiling and diagnostic tools and Natera's personalized circulating tumor DNA (ctDNA) platform Signatera will be used for treatment monitoring and assessment of MRD.

The nonexclusive deal calls for Natera to validate the design of Signatera personalized ctDNA assays using matched tumor and normal exome sequence data from Personalis. Natera will be responsible for commercialization. The agreement covers MRD testing for clinical and research use.

Natera prenatal test gets extended insurance coverage
Healthcare insurer Centene has extended coverage of Natera's Panorama noninvasive prenatal test to all pregnant women. Panorama identifies a fetus's risk...
Natera wins Medicare coverage for colorectal cancer test
Natera has received local coverage determination from the U.S. Centers for Medicare and Medicaid Services for serial use of the Signatera molecular residual...
Natera to collaborate with MGH on breast cancer trial
Natera plans to collaborate with Massachusetts General Hospital (MGH) on a clinical trial that will test the effectiveness of ribociclib (Kisqali) in...
Personalis launches NeXT Dx cancer profiling test
Personalis has announced the launch of its NeXT Dx comprehensive genomic profiling laboratory-developed test, which is designed for use by oncologists...
Merck KGaA, Personalis team up on cancer biomarkers
Merck KGaA will use the ImmunoID NeXT immunogenomics platform of Personalis to develop biomarkers for cancer therapies through a new collaboration.

Copyright © 2021

Last Updated ls 2/17/2021 4:44:52 PM